Introduction {#s1}
============

Lung cancer is one of the most commonly diagnosed malignancies and the leading cause of cancer-related death in the world [@pone.0095915-Jemal1]. Cigarette smoking is considered as an important risk factor for lung cancer. However, only 10--15% of smokers develop lung cancer, suggesting that individual variation in genetic susceptibility to lung cancer in the general population may play a role. Cancer stem cells (CSCs) are a small minority of cells in a heterogeneous tumor population that drives tumor growth and have been associated with resistance to chemo- and radiation-therapies [@pone.0095915-Soltanian1]--[@pone.0095915-Keysar1]. It has been demonstrated that lung CSCs play an important role in tumor initiation [@pone.0095915-Reya1], [@pone.0095915-AlHajj1]. CDCs also share some similarities with normal stem cells, including self-renewal and differentiation, in addition to their potent tumor-driving capability [@pone.0095915-Clarke1]--[@pone.0095915-Sales1]. CSCs are characterized by expression of particular molecular markers that play an important role in promoting stem cell self-renewal and maintenance [@pone.0095915-Marhaba1].

Aberrant expression of CSC markers is associated with the initiation and development of lung cancer, including cluster of differentiation 133 (CD133), Musashi RNA-binding protein 1 (*Musashi-1*), aldehyde dehydrogenase 1 (ALDH1), epithelial cell adhesion molecule (EpCAM), B-cell-specific moloney murine leukemia virus integration site 1 (Bmi-1), Octarner binding factor 4 (OCT-4), and Glycine dehydrogenase (GLDC) [@pone.0095915-Zhang1]--[@pone.0095915-vanderGun1]. CD133, initially described as a surface antigen specific for human hematopoietic stem cells [@pone.0095915-Miraglia1], [@pone.0095915-Yin1], is now being used as an isolation marker of CSCs from lung cancer [@pone.0095915-Eramo1]. *Musashi-1*, an RNA-binding protein, is expressed in various epithelial stem cells and plays an important role in regulating the maintenance and differentiation of stem/precursor cells [@pone.0095915-Okano1]--[@pone.0095915-Kaneko1]. *Musashi-1* is over-expressed in several tumor tissues, including lung cancer [@pone.0095915-Moreira1], gliomas [@pone.0095915-Kanemura1], intestinal adenomas [@pone.0095915-Wang1], [@pone.0095915-Fan1] and hepatomas [@pone.0095915-Shu1], suggesting a correlation with oncogenic development. ALDH1 is widely regarded as a surface marker of CSCs in lung cancer [@pone.0095915-Ginestier1]--[@pone.0095915-Liang1]. ALDH positive lung cancer stem-like cells have longer telomeres than the non-CSC cells [@pone.0095915-Serrano1]. EpCAM, a type I transmembrane glycoprotein of ∼40 kDa, is overexpressed in a variety of epithelial tumors, including lung cancer [@pone.0095915-Went1]--[@pone.0095915-vanderGun1]. EpCAM is involved in intercellular adhesion and interacts with E-cadherin to induce cell adhesion [@pone.0095915-Litvinov1]. Overexpression of EpCAM is linked directly to stimulation of the cell cycle and proliferation by upregulating c-myc and cyclin A/E [@pone.0095915-Munz1]. Inhibition of EpCAM by small inhibitory RNA diminishes cell proliferation, migration and invasiveness [@pone.0095915-Osta1].

Together, these observations have correlated aberrant function of CSC marker molecules with cellular hallmarks of cancer: hyperproliferation and metastatic behaviors. While SNPs have been extensively studied for their association with the risk and prognosis of cancers, little is known about the potential role of SNPs in CSC marker genes with relation to cancer. In this study, we examined the association of lung cancer risk in a Chinese population with polymorphisms of the well-established CSC marker genes CD133, ALDH1, *Musashi-1* and EpCAM. A forecasting model was constructed using CSC marker SNPs and epidemiologic factors; the results provide a novel method to predict individuals at increased risk of developing lung cancer.

Methods {#s2}
=======

Study population {#s2a}
----------------

We conducted a hospital-based, case-control study involving a total of 1000 subjects from northeastern China (Changchun City, Jilin province). All subjects were local residents of Han descent, consisting of 500 patients clinically diagnosed with lung cancer and 500 cancer-free controls. Patients had histologically-confirmed primary lung cancer without previous cancer history, did not receive radiotherapy, chemotherapy or other anti-cancer therapy. Controls were randomly selected normal individuals receiving routine physical examinations in the same hospital. Case matching was performed based on age, gender and place of residence. The study was approved by the Ethics Committee of the First Hospital of Jilin Medical University, and conducted according to the Declaration of Helsinki Principles. All subjects were provided written informed consent.

Diagnostic criteria and Data Collection {#s2b}
---------------------------------------

A standardized interview was conducted by trained interviewers in the hospital or at the homes of participating individuals. Information regarding socio-demographic details, medical history, family history, lifestyle history, and cancer diagnosis was recorded. Risk factor information and peripheral blood lymphocytes were collected at the time of diagnosis for cancer patients or on the day of interview for controls.

CSC marker gene polymorphism selection {#s2c}
--------------------------------------

We used a candidate gene approach [@pone.0095915-Amos1]--[@pone.0095915-Leng1] to select SNPs for this study. Four well-established CSC marker genes (CD133, ALDH1, *Musashi-1* and EpCAM) were selected in the study design. Expression of these four proteins had been reported as a marker to identify lung CSCs [@pone.0095915-Eramo2], [@pone.0095915-Koren1].

Three predefined criteria were used for CSC SNP selection: (a) minor allele frequency (MAF) ≥5% in the HapMap CHB population; (b) SNPinfo website (<http://snpinfo.niehs.nih.gov>) for candidate CSC gene SNP selection, and (c) publications showing clinical correlations with cancer risk/outcome or recurrence. Using these criteria, five CSC candidate SNPs were chosen in our model analysis: Rs2286455 in the CD133 gene, rs1342024 and rs13959 in the ALDH1 gene, rs2522137 in the *Musashi-1* gene, and rs17036526 in the EpCAM gene (**Table 1**). Based upon literature information, we excluded polymorphisms previously implicated in COPD or lung cancer. Additionally, we did not select SNPs in genes encoding proteins involved in pathways of cell-cycle control, oxidant response, apoptosis and airways inflammation. Finally, we avoided SNPs known to have either functional effects on in vitro assays, or were non-synonymous or in regulatory regions.

10.1371/journal.pone.0095915.t001

###### **Table 1.** Single nucleotide polymorphisms in cancer stem cell marker genes.

![](pone.0095915.t005){#pone-0095915-t005-5}

  Gene          SNP       Base exchange     Gene location            Reference
  --------- ------------ --------------- ------------------- -------------------------
  CD133      rs2286455        G\>A           Splice Site                nd
  ALDH1A1    rs1342024        G\>C            Upstream        [@pone.0095915-Gerger1]
              rs13959         C\>T        Synonymous coding             nd
  MSI-1      rs2522137        T\>G             3′ UTR                   nd
  EpCAM      rs17036526       G\>C           Splice site                nd

UTR: untranslated region; nd: no data.

Genotyping and quality control {#s2d}
------------------------------

Genomic DNA was isolated from peripheral blood lymphocytes. MassArray (Sequenom, San Diego, CA) was used to genotype CSC markers using allele specific MALDI--TOF mass spectrometry. Primers and multiplex reactions were designed using the RealSNP.com Website. Concordance among the 3 genomic control DNA samples present in duplicate was 100%. Of the SNPs with genotyping data, the sample call rates were more than 95%.

Statistical analysis {#s2e}
--------------------

The Hardy-Weinberg equilibrium (HWE) was tested by a best fit chi-square (χ^2^) test that compared expected genotype frequencies with observed genotype frequencies in cancer-free controls. The model was also used to determine the presence of significant differences in genotype and allele distribution as well as SNP frequency between clinically diagnosed lung cancer and controls. A logistic regression model was used to identify independent risk factors for lung cancer. The forward stepwise likelihood ratio method was employed to screen variables in model selection, where the cut-off for variables in the model was 0.05 and the cut-off for variables outside of model was 0.10; an optimal model with minimum akaike information criterion was selected. All categorical variables were set as dummy variables, and the first category of each variable was selected as baseline. The classification ability of the model was evaluated using the area under the receiver operating characteristic (ROC) curve (AUC), and the optimal operating point (OPP) was given afterwards. All analyses were conducted using SPSS v19.0 software (SPSS, Inc., Chicago, IL, USA). All P-values were two-sided, and P-values \<0.05 were considered statistically significant.

Results {#s3}
=======

Distribution of genotype and its characteristics in cancer and control populations {#s3a}
----------------------------------------------------------------------------------

We recruited 500 cases of lung cancer and 500 cancer free controls between 2010 and 2012. [**Table 2**](#pone-0095915-t001){ref-type="table"} shows the distribution and frequency of study-specific risk factors between cancer patients and controls.

10.1371/journal.pone.0095915.t002

###### Distribution of CSC marker genotypes and characteristics of the case group and the healthy control group.
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  Characteristic                 Case group             Control group   
  -------------------- ------------------------------ ----------------- ----------------
  rs2286455                          AA                   46 (9.2%)        37 (7.4%)
                                     GG                  266 (53.2%)      262 (52.4%)
                                     GA                  188 (37.6%)      201 (40.2%)
  rs1342024                          GG                  97 (19.4%)        92 (18.4%)
                                     CC                  164 (32.8%)      166 (33.2%)
                                     GC                  239 (47.8%)      242 (48.4%)
  rs13959                            TT                  89 (17.8%)        99 (19.8%)
                                     CC                  176 (35.2%)      159 (31.8%)
                                     CT                  235 (47.0%)      242 (48.4%)
  rs2522137                          TT                  219 (43.8%)      219 (43.8%)
                                     GG                  67 (13.4%)        39 (7.8%)
                                     GT                  214 (42.8%)      242 (48.4%)
  rs17036526                         GG                  224 (44.8%)      233 (46.6%)
                                     CC                  55 (11.0%)        65 (13.0%)
                                     CG                  221 (44.2%)      202 (40.4%)
  Gender                            male                  305 (61%)       302 (60.4%)
                                   female                 195 (39%)       198 (39.6%)
  Age                               \<30                  2 (0.4%)          5 (1.0%)
                                   30--39                 14 (2.8%)        16 (3.2%)
                                   40--49                64 (12.8%)        70 (14.0%)
                                   50--59                176 (35.2%)      196 (39.2%)
                                   60--69                174 (34.8%)      148 (19.7%)
                                    ≥70                  70 (14.0%)        65 (13.0%)
  Education             Junior high school and lower     318 (63.6%)      130 (26.0%)
                                High school              97 (19.4%)       144 (28.8%)
                          Greater than high school       85 (17.0%)       226 (45.2%)
  Smoking                        Pack years            14.25 (0--36.0)   0.0 (0.0--6.9)
  exposure to                      Absent                398 (79.6%)      473 (94.6%)
  Pesticide                       Present                102 (20.4%)       27 (5.4%)
  exposure to                      Absent                487 (97.4%)      496 (99.2%)
  Gasoline/diesel                 Present                 13 (2.6%)         4 (0.8%)
  exposure to Ink                  Absent                493 (98.6%)      497 (99.4%)
                                  Present                 7 (1.4%)          3 (0.6%)
  Cooking emissions                Absent                244 (48.8%)      250 (50.0%)
  (Total dish-years)                ≤50                 149 (29.8%))      152 (30.4%)
                                  51--100                61 (12.2%)        80 (16.0%)
                                  101--150                46 (9.2%)        18 (3.6%)
  Pneumonia                    History Absent            477 (95.4%)      490 (98.0%)
                              History Present             23 (4.6%)        10 (2.0%)
  COPD                         History Absent            449 (89.8%)      489 (97.8%)
                              History Present            51 (10.2%)        11 (2.2%)
  Pulmonary                    History Absent            470 (94.0%)      486 (97.2%)
  tuberculosis                History Present             30 (6.0%)        14 (2.8%)
  Bronchial asthma             History Absent            488 (97.6%)      495 (99.0%)
                              History Present             12 (2.4%)         5 (1.0%)
  Family history               History Absent            330 (66.0%)      397 (79.4%)
  of cancer                   History Present            170 (34.0%)      103 (20.6%)
  BMI                              \<18.5                 49 (9.8%)        15 (3.0%)
  (kg/m^2^)                       18.5--24               302 (60.4%)      230 (46.0%)
                                    ≥24                  149 (29.8%)      255 (51.0%)

Association of CSC marker gene SNPs with lung cancer risk in univariate analysis {#s3b}
--------------------------------------------------------------------------------

We first evaluated lung cancer risk using univariate analysis. Among CSC marker gene SNPs selected, the *Musashi-1* rs2522137 GG genotype had a tendency toward a higher incidence of lung cancer than the rs2522137 GG genotype in both recessive model (P = 0.004) and additive model. However, no significant differences were noticed for SNPs in other CSC marker genes in dominant, recessive, additive, or multiplicative models ([**Table 3**](#pone-0095915-t002){ref-type="table"}).

10.1371/journal.pone.0095915.t003

###### Association of SNPs with lung cancer risk in univariate analysis.
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                          Genotype   Univariate OR (95%CI)   P value
  ---------------------- ---------- ----------------------- ---------
  rs17036526                                                
  Recessive model         CC + GC              1              0.568
                             GG      0.930 (0.725--1.193)   
  Dominant model             CC                1              0.331
                          GG + GC    1.209 (0.825--1.773)   
  Additive model             CC                1            
                             GC      1.293 (0.861--1.942)     0.216
                             GG      1.136 (0.759--1.700)     0.535
  Multiplicative model    G allele   1.004 (0.837--1.205)     0.963
  rs2522137                                                 
  Dominant model             TT                1              1.000
                          GG + TG    1.000 (0.779--1.284)   
  Recessive model         TT + TG              1              0.004
                             GG      1.829 (1.207--2.733)   
  Additive model             TT                1            
                             TG      0.884 (0.680--1.150)     0.359
                             GG      1.718 (1.110--2.6591)    0.015
  Multiplicativemodel     G allele   1.138 (0.942--1.374)     0.179
  rs2286455                                                 
  Recessive model         GG + GA              1              0.303
                             AA      1.268 (0.807--1.992)   
  Dominant model             GG                1              0.800
                          AA + GA    0.968 (0.755--1.241)   
  Additive model             GG                1            
                             GA      0.921 (0.709--1.197)     0.540
                             AA      1.225 (0.769--1.950)     0.393
  Multiplicative model    A allele   0.963 (0.803--1.153)     0.806
  rs1342024                                                 
  Recessive model         CC + CG              1              0.686
                             GG      1.067 (0.778--1.465)   
  Dominant model             CC                1              0.893
                          GG + CG    1.018 (0.782--1.325)   
  Additive model             CC                1            
                             CG      1.000 (0.755--1.323)     0.998
                             GG      1.067 (0.746--1.526)     0.722
  Multiplicative model    G allele   1.028 (0.863--1.226)     0.754
  rs13959                                                   
  Recessive model         TT + TC              1              0.255
                             CC      1.165 (0.896--1.515)   
  Dominant model             TT                1              0.418
                          CC + TC    1.140 (0.830--1.566)   
  Additive model             TT                1            
                             TC      1.080 (0.770--1.514)     0.655
                             CC      1.231 (0.861--1.761)     0.254
  Multiplicative model    C allele   1.114 (0.935--1.327)     0.228

Association of SNPs with lung cancer risk in multivariate analysis {#s3c}
------------------------------------------------------------------

Next, we evaluated independent risk factors of lung cancer using multivariate analysis. By incorporating environmental and lifestyle parameters, we found that in the recessive model, *Musashi-1* rs2522137 was still significantly associated with lung cancer. These environmental and lifestyle parameters included lower BMI, family history of cancer, prior diagnosis of COPD, pneumonia or pulmonary tuberculosis, occupational exposure to pesticide, occupational exposure to gasoline or diesel, heavier smoking, and exposure to heavier cooking emission (**Table 4**). These data suggest that the *Musashi-1* rs2522137 GG genotype is a significant genetic risk factor for lung cancer.

10.1371/journal.pone.0095915.t004

###### **Table 4.** Multivariate risk model with adjusted odds ratios and 95% confidence intervals.
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  Risk factors                          Exp (B)       95% C.I.       P value
  ------------------------------------ --------- ------------------ ---------
  Occupational exposure to pesticide                                
  Absence                                1.00        Reference        0.000
  Presence                               3.390     (2.093--5.493)   
  exposure to gasoline/diesel:                                      
  Absence                                1.00        Reference        0.012
  Presence                               4.653    (1.402--15.448)   
  Smoking                                1.032     (1.024--1.041)     0.000
  Cooking emission(Total dish-years)                                  0.001
  ≤50                                    1.00        Reference      
  51--100                                1.304     (0.934--1.819)     0.119
  101--150                               0.941     (0.608--1.457)     0.785
  \>150                                  3.375     (1.779--6.402)     0.000
  COPD:                                                             
  History absence                        1.00        Reference        0.000
  History presence                       3.775     (1.809--7.878)   
  Pneumonia:                                                        
  History presence                       1.00        Reference        0.021
  History absence                        0.369     (0.158--0.860)   
  Pulmonary tuberculosis:                                           
  History presence                       1.00        Reference        0.022
  History absence                        0.428     (0.207--0.884)   
  Family history of cancer:                                         
  History absence                        1.00        Reference        0.000
  History presence                       1.848     (1.338--2.553)   
  BMI(kg/m2):                                                         0.000
  \<18.5                                 1.00        Reference      
  18.5--24                               0.370    (0. 192--0. 714)    0.003
  ≥24                                    0.168    (0.086--0. 328)     0.000
  rs2522137:                                                        
  TT+TG                                  1.00        Reference      
  GG                                     1.926     (1.209--3.070)     0.006

COPD: chronic obstructive pulmonary disease

ROC analysis {#s3d}
------------

The classification ability of the multivariate model was further evaluated using the area under ROC curve (AUC) and the optimal operating point (OPP). [**Figure 1**](#pone-0095915-g001){ref-type="fig"} shows the ROC curve derived from our model; AUC was calculated as 0.7686. Furthermore, the OPP was obtained when the cutoff was set at 0.47. The estimated false positive rates, true positive rates, and Youden index were determined to be 0.28, 0.72, and 0.44, respectively.

![ROC plots for lung cancer risk prediction model.\
The ROC AUC was 0.7686. The straight line represented the ROC curve expected by chance alone.](pone.0095915.g001){#pone-0095915-g001}

Correlation between SNPs and lung cancer type {#s3e}
---------------------------------------------

Finally, we looked for correlations between CSC SNPs and lung cancer type (squamous cell, adenocarcinoma, small cell) along with age at onset and gender of lung cancer. We did not observe statistically significant differences between these CSC SNPs and age or gender at the onset of lung cancer ([**Tables 5**](#pone-0095915-t003){ref-type="table"}). In the pathology-stratified analysis, however, CD133 SNP rs2286455 was significantly correlated with lung cancer type (P = 0.048) ([**Table 6**](#pone-0095915-t004){ref-type="table"}). No differences were observed between the remaining SNPs being considered with lung cancer type.

10.1371/journal.pone.0095915.t005

###### Association of SNPs with gender and age from lung cancer patients.
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  Characteristic    Gender   *P* value   Age (yrs.)   *P* value                
  ---------------- -------- ----------- ------------ ----------- ------------- -----------
  rs2286455           AA        29           17         0.184     58.87±10.18   reference
                      GG        171          95                   57.07±11.34     0.257
                      GA        105          83                   59.02±9.22      0.872
  rs1342024           CC        99           65         0.806     58.85±9.95    reference
                      GG        62           35                   59.86±9.95      0.432
                      GC        144          95                   58.25±9.93      0.550
  rs13959             CC        103          73         0.574     59.36±9.78    reference
                      TT        58           31                   60.15±9.84      0.541
                      CT        144          91                   57.79±10.03     0.112
  rs2522137           GG        39           28         0.877     58.27±10.52   reference
                      TT        135          84                   58.07±10.15     0.885
                      GT        131          83                   59.62±9.50      0.331
  rs17036526          CC        31           24         0.740     59.80±9.90    reference
                      GG        139          85                   58.90±9.08      0.547
                      CG        135          86                   58.36±10.76     0.338

\*M, male; F, female.

10.1371/journal.pone.0095915.t006

###### Association of SNPs with histology types from lung cancer patients.
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  Characteristic    Histology types   *P* value                 
  ---------------- ----------------- ----------- ---- ---- ---- -------
  rs2286455               AA             78       93   70   25   0.048
                          GG             10       16   18   2   
                          GA             53       67   38   30  
  rs1342024               CC             41       59   43   21   0.640
                          GG             30       39   20   8   
                          GC             70       78   63   28  
  rs13959                 CC             49       64   42   21   0.324
                          TT             23       39   22   5   
                          CT             69       73   62   31  
  rs2522137               GG             21       25   18   3    0.361
                          TT             65       69   59   26  
                          GT             55       82   49   28  
  rs17036526              CC             15       19   13   8    0.780
                          GG             70       76   52   26  
                          CG             56       81   61   23  

\* SQ: squamous cell; AD, adenocarcinoma; SC, small cell; OC, other carcinomas.

Discussion {#s4}
==========

Single nucleotide polymorphisms (SNPs) have been extensively examined in practically all cancer types in an effort to identify inherited cancer susceptibility genes and their interaction with environmental factors. Cancer stem cells (CSCs) play an important role in tumor initiation, metastases, and recurrence. We have examined the potential correlation between SNPs present in CSCs and the likelihood of lung cancer. This is particularly important since SNPs in CSC-directing genes could provide a genetic link to cancers that are particularly challenging to treat. While typical cancer therapies may eliminate most of the tumor mass, a small population of CSCs with the potential to repopulate the tumor may remain [@pone.0095915-Reya1]. It is generally accepted that CSCs are characterized by the unique expression of cell surface molecules called CSC marker genes. CSC markers play an important part in the maintenance of self-renewal and resistance to apoptosis pathway activation in these cells. In this study, we obtained information to support the hypothesis that clinical outcome in lung cancer patients may be influenced by genetic variants of CSC marker genes.

The potential impact of CSC marker gene polymorphisms on lung cancer susceptibility has not been previously explored. In this study we took the advantage of a hypothesis-driven candidate gene approach [@pone.0095915-Amos1]--[@pone.0095915-Leng1] to identify potentially functional SNPs associated with histologically validated lung cancer. In contrast to genome-wide association (GWA) and quantitative trait locus (QTL) approaches, the candidate gene approach is economical and has rather high statistical power [@pone.0095915-Amos1]. We focused on four CSC marker genes that have been used to isolate CSCs: CD133, ALDH1, EpCAM, and *Musashi-1* [@pone.0095915-Eramo2], [@pone.0095915-Koren1]. Using the candidate gene approach, we selected a panel of SNPs in these CSC gene loci from SNP websites and peer-reviewed literature. SNPs identified to have high allele frequency were genotyped in 500 lung cancer cases along with 500 age-matched controls. Our results have identified the *Musashi-1* variant as an independent risk factor for lung cancer. It is also interesting to note that the *Musashi-1* rs2522137 genotype was still associated with lung cancer risk in a multivariate regression model that considered several environmental and lifestyle factors. Taken together, this study provides the first evidence to correlate the *Musashi-1* rs2522137 SNP variant with lung cancer.

Currently, we know very little about the detailed molecular mechanisms by which *Musashi-1* rs2522137 polymorphisms might contribute to lung cancer development. *Musashi-1* is an evolutionarily conserved RNA-binding protein that has profound implications in cellular processes, such as stem cell maintenance, nervous system development, and tumorigenesis. *Musashi-1* is highly expressed in many cancers, whereas in normal tissues, its expression is restricted only to stem cells. It is now clear that this RNA-binding protein is involved in cell asymmetric division and is required for the maintenance of stem cell identity [@pone.0095915-Siddall1]--[@pone.0095915-Nishimura1]. Interestingly, *Musashi-1* mRNA transcript contains an 1811-bp long 3′-untranslated region (3′-UTR). The 3′-UTR of mRNA transcripts usually buries the target site for regulatory microRNA (miRNA). SNPs in the 3′-UTRs have been shown to have functional effects on control of mRNA stability and/or translational efficiency through the regulation of miRNA. The binding of miRNAs to the 3′-UTRs may play an important overall role in gene expression.

The 3′-UTR of mature *Musashi-1* mRNA is potentially targeted by several tumor suppressor miRNAs, including miR-34a, -101, -128, -137 and -138 [@pone.0095915-Vo1]. In addition, the *Musashi-1* mRNA 3′-UTR contains several AU- and U-rich sequences that are targeted by an evolutionarily conserved RNA-binding protein HuR [@pone.0095915-Vo2]. HuR is a member of the Hu/ELAV (embryonic lethal abnormal vision) family, which is highly expressed in tumor tissue and enhances tumorigenesis by interacting with a subset of mRNAs that encode proteins in the regulation of cell proliferation, cell survival, angiogenesis, invasion, and metastasis [@pone.0095915-Barreau1], [@pone.0095915-Abdelmohsen1]. Using the SNPinfo website (<http://snpinfo.niehs.nih.gov/>), we found that the *Musashi-1* 3′-UTR also buries potential target sites for miRNAs hsa-miR-1275, hsa-miR-1285, hsa-miR-483-5p, hsa-miR-486-3p, hsa-miR-612, and hsa-miR-625. It is worthwhile noting that *Musashi-1* rs2522137 is located within these miRNA and HuR binding sites. Future studies are needed to delineate whether rs2522137 variants may affect the binding of these regulatory miRNAs and HuR protein. Presumably, the *Musashi-1* rs2522137 GG variant may interfere with the binding of miRNAs and HuR factor, thus increasing the stability of *Musashi-1* mRNA. If true, this mechanism could provide the basis for the *Musashi-1* rs2522137 variant to maintain self-renewing lung cancer stem cells.

SNPs represent inherited genetic variations that occur during the lifetime of an individual. It is well known that non-genetic risk factors, such as age, history of lung disease, and smoking history are also very important and can be combined to develop risk-based models of cancer. Robert et al [@pone.0095915-Young1], [@pone.0095915-Young2] have suggested that SNPs need to be combined with other risk variables to identify individuals who are most susceptible to developing lung cancer. Similarly, the Liverpool Lung Project risk model improves its predictive capability of lung cancer by adding a marker SNP (rs663048) in the SEZ6L gene [@pone.0095915-Cassidy1], [@pone.0095915-Raji1]. In this study, we identified a correlation between lung cancer and a specific SNP within a CSC marker gene. Environmental and lifestyle factors included in this analysis, such as occupational exposure to pesticide, occupational exposure to gasoline/diesel prior diagnosis of pulmonary tuberculosis, and cooking emission, provide a similar correlation relative to an age-matched control population.

In summary, this study revealed a significantly increased risk of lung cancer for the CSC marker *Musashi-1* rs2522137-GG compared with -TT and -TG SNPs in a Chinese population. The ROC AUC of our model was 0.7686, indicating the potential to identify high-risk individuals in the Chinese population by focusing on information that can be readily obtained in the primary care setting. Finally, this lung cancer risk prediction model discriminated between high- and low-risk individuals. Further studies are needed in larger cohorts of unselected cases and controls to further validate and extent these initial observations.
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